Agreement to develop long-acting rilpivirine as PrEP
1 December 2013. Related: Prevention.
On 25 September 2013, Janssen announced that it had signed a license agreement with international nonprofit health organisation PATH for early stage research to develop a long acting depot formulation of rilpivirine as a potential pre-exposure prophylaxis (PrEP) against HIV. 
PATH is planning to collaborate with partners including the HIV Prevention Trials Network for future research for these initial phase 2 studies, and this initiative is funded by the Bill & Melinda Gates Foundation. 
Rilpivirine is an NNRTI currently licensed as an oral drug in ARV treatment-naïve adults with a viral load less than or equal to 100,000 copies/mL and is coformulated with tenofovir/FTC in the fixed dose combination Eviplera (Edurant in the US).
- Jannsen press statement. Janssen R&D Ireland announces agreement with PATH for early development of rilpivirine in long-acting formulation for potential prophylactic intervention, (25 September 2013).
- PATH press release. New partnership advances drug formulation that could help prevent HIV infection, (25 September 2013).